Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of JNJ-16269110 in overweight and obese subjects with type 2 diabetes mellitus
2006-006772-38Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of usistapide in obesity (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change in body weight at Week 12 and Safety and tolerability of JNJ-16269110. Started Aug 2007; status: completed.
02
Drugs
usistapide
03
Conditions
obesity
Beyond the preview
Go deeper on 2006-006772-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006772-38.